Advertisements


Intercept Reports Phase III Sub-Study Liver Biopsy Data

Intercept (ICPT) announces data from the POISE biopsy sub-study which showed that treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patien.....»»

Category: worldSource: nytApr 16th, 2018

Intercept announces data from liver biopsy substudy of POISE Phase 3 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 13th, 2018

Merck Reports Positive Phase III Liver Cancer Data on Keytruda

Merck (MRK), announces first time results from the phase II study evaluating the use Keytruda in patients with advanced hepatocellular carcinoma (HCC), previously treated with sorafenib. Merck & Co., Inc. MRK announced data f.....»»

Category: personnelSource: nytJan 22nd, 2018

Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress

− Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Myeloma Remains on Track; Top-Line Data Expected end of April 2018 –.....»»

Category: earningsSource: benzingaMar 15th, 2018

Anthera Pharmaceuticals (ANTH) Reports Top Line Data From The RESULT Phase 3 Clinical Study Of Sollpura - Slideshow

Anthera Pharmaceuticals (ANTH) Reports Top Line Data From The RESULT Phase 3 Clinical Study Of Sollpura - Slideshow.....»»

Category: topSource: seekingalphaMar 13th, 2018

Epizyme Reports Fourth Quarter and Full Year 2017 Operating Results and 2018 Milestones

First Tazemetostat NDA Submission for Epithelioid Sarcoma Targeted for Fourth Quarter of 2018; Second Tazemetostat NDA Submission for Follicular Lymphoma Targeted for 2019 Multiple Phase 2 Study Data Readouts Planned in 2018 Confer.....»»

Category: earningsSource: benzingaMar 13th, 2018

Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress

Initial Clinical Data of FATE-NK100 in Relapsed / Refractory AML Show Rapid Reduction of Leukemic Blasts in the Bone Marrow All Subjects in PROTECT Phase 1 Study of ProTmune Ac.....»»

Category: earningsSource: benzingaMar 5th, 2018

Bristol-Myers (BMY) Reports Data from CheckMate-142 Study

Bristol-Myers (BMY) announces new data from a cohort of the phase II CheckMate -142 study evaluating Opdivo (nivolumab) and Yervoy (ipilimumab). Bristol-Myers Squibb Company BMY announced new d.....»»

Category: dealsSource: nytJan 22nd, 2018

Momenta Reports Positive Top-Line Data on Antibody M281

Momenta reported positive top-line results from a phase I study on M281 wherein the candidate did not show any adverse event.....»»

Category: smallbizSource: nytJan 8th, 2018

Juno Reports Additional Data on CAR-T Therapy, Shares Drop

Juno (JUNO) releases additional results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate, JCAR017. Juno Therapeutics, Inc. JUNO along with partner Celgene Corporation CE.....»»

Category: worldSource: nytDec 12th, 2017

Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug

Bristol-Myers Squibb Company (BMY) announced positive data from an ongoing phase II study on leukemia drug Sprycel in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone for two years. .....»»

Category: worldSource: nytDec 12th, 2017

Incyte (INCY) Reports Phase III Follow-Up Data for Jakafi

Incyte (INCY) announced new 208-week (4-year) follow-up data from the phase III RESPONSE study of Jakafi. Incyte Corporation INCY announced a new 208-week (4-year) follow-up data from the phase III RESPONSE study of Jakafi. The .....»»

Category: worldSource: nytDec 11th, 2017

Roche Reports Tecentriq/Avastin Lung Cancer Study Data

Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer. Roche’s RHHBY member Genentech, annou.....»»

Category: personnelSource: nytDec 7th, 2017

Pfizer Reports Updated Data from Phase III Study on Ibrance

Pfizer (PFE) releases impressive new data of a post-hoc analysis from a phase III study on the combo therapy of Ibrance and Femara for the first-line treatm.....»»

Category: personnelSource: nytDec 7th, 2017

Pfizer Reports Updated Data from Phase III Study on Ibrance

Zacks.....»»

Category: topSource: redinewsDec 7th, 2017

Jounce Therapeutics Reports Third Quarter 2017 Financial Results

- Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC study in 1H 2018 - - Strengthen leadership team and board with key new appointmen.....»»

Category: earningsSource: benzingaNov 13th, 2017

Madrigal Pharmaceuticals Reports 2017 Second Quarter Financial Results

- Completed patient enrollment in Phase 2 clinical study of MGL-3196, a liver-directed thyroid hormone receptor (THR) beta selective agonist, for treatment of NASH ­-             - Raised $35 million f.....»»

Category: earningsSource: benzingaAug 10th, 2017

Jounce Therapeutics Reports Second Quarter 2017 Financial Results

- Presented Phase 1 data from ICONIC study of JTX-2011 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting - - Initiated Phase 2 portion of ICONIC study evaluating JTX-2011 in advanced solid tumors in.....»»

Category: earningsSource: benzingaAug 9th, 2017

Ironwood (IRWD) Reports Positive Data on Reflux Candidate

Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease. Ironwood Pharmaceuticals, Inc. IRWD announced positive top-l.....»»

Category: topSource: zacksJul 21st, 2017

Alnylam (ALNY) Reports Positive Data for RNAi Candidate

Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of a.....»»

Category: worldSource: nytApr 17th, 2018

Dynavax reports interim data for study of SD-101 in combination Merck"s Keytruda

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018